Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 15/20 | 0.56 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.49 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30830977 | 0.90 | CRBN (0.55) | CRBNDDB1GSPT1IKZF3ALDH1A1 | |
| SCHEMBL29116380 | 0.88 | CRBN (0.56) | CRBNDDB1GSPT1IKZF3ALDH1A1 | |
| SCHEMBL27290604 | 0.87 | CRBN (0.56) | CRBNDDB1GSPT1IKZF3ALDH1A1 | |
| SCHEMBL24654197 | 0.86 | CRBN (0.50) | CRBNDDB1GSPT1IKZF3ALDH1A1 | |
| SCHEMBL23705554 | 0.86 | CRBN (0.55) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL29617046 | 0.86 | CRBN (0.55) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL31217690 | 0.86 | CRBN (0.55) | CRBNDDB1GSPT1IKZF3ALDH1A1 | |
| SCHEMBL24819306 | 0.85 | IKZF1 (0.58) | CRBNDDB1GSPT1IKZF3 | |
| SCHEMBL31254134 | 0.85 | CRBN (0.65) | CRBNDDB1GSPT1 | |
| SCHEMBL30658467 | 0.85 | IKZF1 (0.58) | CRBNDDB1GSPT1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| EP-4051674-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-09-07 | — | — | EP | disclosed |
| CN-114728936-A | Bifunctional compounds for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021083949-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-06 | — | — | WO | disclosed |